Incyte | INCY - Interest Expense On Debt

Stock Price
101.66
Daily Change
0.74 0.73%
Monthly
-0.13%
Yearly
35.08%
Q1 Forecast
96.99

Incyte reported $592K in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 254M 6M Jun/2025
Incyte USD 592K 2K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025